Puneet Souda
Stock Analyst at Leerink Partners
(1.97)
# 3,049
Out of 5,173 analysts
220
Total ratings
46.93%
Success rate
-1.26%
Average return
Main Sectors:
Stocks Rated by Puneet Souda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Outperform | $170 → $180 | $84.96 | +111.86% | 8 | Feb 20, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $545 → $580 | $478.12 | +21.31% | 20 | Oct 22, 2025 | |
| HOLX Hologic | Maintains: Market Perform | $70 → $78 | $75.64 | +3.12% | 8 | Oct 21, 2025 | |
| CYRX Cryoport | Upgrades: Outperform | $16 | $8.15 | +96.32% | 7 | Aug 6, 2025 | |
| MASS 908 Devices | Upgrades: Outperform | $12 | $6.11 | +96.40% | 7 | Aug 5, 2025 | |
| QTRX Quanterix | Downgrades: Market Perform | $12 → $8 | $3.94 | +103.05% | 12 | Apr 30, 2025 | |
| NEO NeoGenomics | Downgrades: Market Perform | $25 → $9 | $8.10 | +11.11% | 10 | Apr 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Market Perform | $30 → $21 | $4.66 | +350.64% | 7 | Dec 9, 2024 | |
| VCYT Veracyte | Maintains: Outperform | $35 → $40 | $33.54 | +19.26% | 14 | Oct 17, 2024 | |
| NTRA Natera | Maintains: Outperform | $140 → $150 | $200.09 | -25.03% | 7 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $325 → $375 | $301.81 | +24.25% | 15 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $35 | $25.75 | +35.92% | 11 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $145 | $112.02 | +29.44% | 19 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $300 | $190.00 | +57.89% | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $249 → $250 | $123.79 | +101.95% | 19 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $110 | $52.00 | +111.54% | 6 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $104.91 | -28.51% | 16 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $200 | $116.35 | +71.90% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $3.37 | +434.12% | 6 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $1.76 | +240.91% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $45 → $30 | $44.50 | -32.58% | 6 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $87 | $34.86 | +149.57% | 13 | May 5, 2022 |
Guardant Health
Feb 20, 2026
Maintains: Outperform
Price Target: $170 → $180
Current: $84.96
Upside: +111.86%
Thermo Fisher Scientific
Oct 22, 2025
Maintains: Outperform
Price Target: $545 → $580
Current: $478.12
Upside: +21.31%
Hologic
Oct 21, 2025
Maintains: Market Perform
Price Target: $70 → $78
Current: $75.64
Upside: +3.12%
Cryoport
Aug 6, 2025
Upgrades: Outperform
Price Target: $16
Current: $8.15
Upside: +96.32%
908 Devices
Aug 5, 2025
Upgrades: Outperform
Price Target: $12
Current: $6.11
Upside: +96.40%
Quanterix
Apr 30, 2025
Downgrades: Market Perform
Price Target: $12 → $8
Current: $3.94
Upside: +103.05%
NeoGenomics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $25 → $9
Current: $8.10
Upside: +11.11%
Myriad Genetics
Dec 9, 2024
Downgrades: Market Perform
Price Target: $30 → $21
Current: $4.66
Upside: +350.64%
Veracyte
Oct 17, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $33.54
Upside: +19.26%
Natera
Oct 17, 2024
Maintains: Outperform
Price Target: $140 → $150
Current: $200.09
Upside: -25.03%
Aug 1, 2024
Upgrades: Outperform
Price Target: $325 → $375
Current: $301.81
Upside: +24.25%
Jun 5, 2023
Maintains: Outperform
Price Target: $50 → $35
Current: $25.75
Upside: +35.92%
May 24, 2023
Maintains: Outperform
Price Target: $170 → $145
Current: $112.02
Upside: +29.44%
May 1, 2023
Initiates: Outperform
Price Target: $300
Current: $190.00
Upside: +57.89%
Feb 8, 2023
Maintains: Outperform
Price Target: $249 → $250
Current: $123.79
Upside: +101.95%
Feb 3, 2023
Maintains: Outperform
Price Target: $125 → $110
Current: $52.00
Upside: +111.54%
Jan 12, 2023
Maintains: Outperform
Price Target: $70 → $75
Current: $104.91
Upside: -28.51%
Jan 6, 2023
Maintains: Outperform
Price Target: $230 → $200
Current: $116.35
Upside: +71.90%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $3.37
Upside: +434.12%
Nov 29, 2022
Initiates: Outperform
Price Target: $6
Current: $1.76
Upside: +240.91%
Nov 21, 2022
Maintains: Market Perform
Price Target: $45 → $30
Current: $44.50
Upside: -32.58%
May 5, 2022
Maintains: Outperform
Price Target: $85 → $87
Current: $34.86
Upside: +149.57%